Alpha Cognition Inc. Announces Milestone Update on ALPHA-1062 and Commercialization Strategy

Written By Kathleen Otto

Alpha Cognition Inc., a biopharmaceutical leader in neurodegenerative disorder treatments, provides a key business update. The company's focus includes its ALPHA-1062 NDA filing for mild-to-moderate Alzheimer’s disease in the US, commercialization strategy, and pipeline progress. ALPHA-1062's NDA was accepted by the FDA on December 06, 2023, with a PDUFA date set for July 27, 2024.

The potential approval would mark a milestone, offering a much-needed oral therapy for Alzheimer’s patients. The company also highlights successful financial positioning and ongoing pre-commercialization efforts, projecting 2024 as a transformative year.

Kathleen Otto
Previous

TheracosBio Extends Collaboration with Mark Cuban Cost Plus Drug Company to Expand Access to BRENZAVVY
Next

Johnson & Johnson's Nipocalimab Granted Breakthrough Designation for Hemolytic Disease Treatment